|
| |
Intercell AGIntercell AG is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prevention and treatment of infectious diseases with substantial unaddressed medical need. The Company's unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP manufacturing facilities. Intercell's technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis undergoing Phase III clinical trials, a vaccine for Hepatitis C in Phase II trials, and five products focused on infectious diseases in the pre-clinical phase. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".
| Contact Details: |
| Campus Vienna Biocenter 6 |
| Vienna |
| |
| 1030 |
| Austria |
| Tel: | 43 1 20 620 0 |
| Fax: | 43 1 20 620 300 |
| Email: | info@intercell.com |
| WWW: | www.intercell.com/
|
| |
Recent Publications by Intercell AG: |  |
Immunogenicity and safety of IXIARO((R)) (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age.
For adults the standard administration of the Japanese encephalitis... | 28th October, 2009
| Intercell AG, Campus Vienna Biocenter 3, A-1030 Vienna, Austria.
| Vaccine. 2009 Oct 24.
DOI Direct Link |
Chemokine degradation by the Group A streptococcal serine proteinase ScpC can be reconstituted in vitro and requires two separate domains.
Streptococcus pyogenes is one of the most common human pathogens and... | 17th September, 2009
| Intercell AG, Campus Vienna Biocenter 3, 1030 Vienna, Austria.
| Biochem J. 2009 Aug 27;422(3):533-42.
DOI Direct Link |
Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.
In travellers often several pre-departure immunizations are indicated,... | 14th August, 2009
| Intercell AG, Campus Vienna Biocenter 3, 1030 Vienna, Austria.
| Vaccine. 2009 Jul 16;27(33):4483-9. Epub 2009 May 30.
DOI Direct Link |
Composition of the ANTIGENome of Helicobacter pylori defined by human serum antibodies.
Helicobacter pylori is the most prevalent human pathogen and although, it... | 23rd July, 2009
| Intercell AG, Campus Vienna Biocenter 5, A-1030 Vienna, Austria.
| Vaccine. 2009 May 26;27(25-26):3251-9. Epub 2009 Feb 5.
DOI Direct Link |
Detection of human cytomegalovirus-specific T lymphocytes in human blood: comparison of two methods.
BACKGROUND: Human cytomegalovirus (HCMV) infection remains a major cause... | 18th July, 2009
| Clinical Immunology Laboratory, Intercell AG, Vienna, Austria.
| Cytotherapy. 2008;10(8):834-41.
DOI Direct Link |
→View more Intercell AG research publications. |
Press Releases on Intercell AG:
|
 |
| Intercell to Webcast Research & Development Day on Thursday, June 4, 2009 |
27th May, 2009 |
Intercell AG |
VIENNA and GAITHERSBURG, Md., May 27 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that it will webcast its Research & Development Day being held in New York on Thursday, June 4
|
| Intercell Executes Multi-Year Contract for Supply of IXIARO(R) to the United States Military |
8th May, 2009 |
Intercell AG |
- Exclusive, multi-year contract executed by Intercell and U.S. Department of Defense for purchase of IXIARO(R)
- First sales of IXIARO under this military contract expected soon
VIENNA, May 8
|
| Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine |
7th April, 2009 |
Intercell AG |
- Initiation of a first-in-man Phase I clinical trial in healthy subjects
- Study aims to obtain safety and immunogenicity data of this new vaccine candidate
- Initial results expected in Q4 2009
-
|
| Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis |
2nd April, 2009 |
Intercell AG |
-- European Commission grants marketing authorization for Intercell's IXIARO, the first licensed vaccine against Japanese Encephalitis for travelers and military personnel in Europe
-- This
|
| Intercell Announces FDA Approval of IXIARO(R), a Vaccine Against Japanese Encephalitis |
31st March, 2009 |
Intercell AG |
A Successful Collaboration with the U.S. Army
- U.S. FDA (Food and Drug Administration) approves Intercell's first marketed product, a new vaccine against Japanese Encephalitis for adult
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 344 times since April 2007, the link to the organisation's website has been followed 57 times Recent Search Terms used to find this page: intercell | Intercell AG contact Dr. Gerd Zettlmeissl CEO | intercell austria | . Search for more companies in Vienna Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Intercell AG |
